Skip to main content

Revisiting vasodilator strategy in sympathetic crashing acute pulmonary edema: A meta-analysis of high-dose nitroglycerin efficacy and safety

Journal
The American journal of emergency medicine (Q1)
Published
19 September 2026
Study design
Systematic review / meta-analysis of RCTs
Evidence level
Level 1, High (CEBM 1a)
Authors
Yana A Jandali, Raghad M Sabbahi, Lareen M Sabi, Talal S Alsharari, Abdulaziz M Muhanna, Rebal N Khayyat, et al.
PMID
42784941
DOI
10.1016/j.ajem.2026.09.014

Why clinicians should know about it

  • Picked for Emergency Medicine (paper of the day, 25 September 2026): High‑dose nitroglycerin in SCAPE, acute pulmonary edema therapy

Abstract

AIM: To evaluate the efficacy and safety of high-dose intravenous nitroglycerin compared with conventional low-dose strategies in patients with SCAPE. METHODS: A comprehensive search of PubMed, Scopus, Web of Science, and Cochrane Library databases was performed from inception to March 2026. Eligible studies included randomized controlled trials (RCTs) and observational studies assessing high-dose NTG (≥100 μg/min or equivalent bolus regimens) in adult patients with SCAPE. RESULTS: Six studies (n = 534 in comparative analysis) were included. No significant differences were observed in intubation rates (RR 0.91; 95% CI, 0.11-7.73), intensive care unit (ICU) admission (RR 0.92; 95% CI, 0.81-1.05), or ICU length of stay (MD -31.29 h; 95% CI, -330.32 to 267.73). Notably, high-dose NTG showed numerically higher estimates of achieving the target systolic blood pressure reduction compared with low-dose NTG (RR 1.70; 95% CI, 0.36-8.10; p = 0.15). High-dose NTG was associated with a modest increase in hypotension risk (RR 1.41; 95% CI, 1.02-1.94). Single-arm analysis demonstrated high rates of symptom resolution (95%) and relatively low intubation (10%) and ICU admission (12%) rates. Subgroup analyses showed rapid improvements in blood pressure, respiratory rate (RR), and oxygenation. CONCLUSION: High-dose intravenous nitroglycerin provides rapid hemodynamic and symptomatic improvement in SCAPE. However, these benefits do not clearly translate into reductions in intubation or ICU utilization and are accompanied by a modest increase in hypotension risk. Interpretation is constrained by variable low-dose comparator definitions, differing high-dose regimens, and inconsistent reporting of co-interventions.

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.